DMD drug developers stake out territory in rare disease market
This article was originally published in Scrip
Executive Summary
Parents of boys with Duchenne muscular dystrophy (DMD) have had little good news during the past few months due to setbacks for Prosensa and Sarepta Therapeutics, but three different biotechnology company presentations at the 32nd Annual JP Morgan Healthcare Conference offered signs of hope for therapies that may keep their sons from losing the ability to walk, eat and breathe on their own.
You may also be interested in...
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.